Literature DB >> 2788063

Isotope retention for assessment of bone turnover in involutional osteoporosis.

M Passeri1, E Palummeri, M C Baroni, F Quaini, A Quintavalla, M Barbagallo, D Franchini, D Ugolotti.   

Abstract

A continuous bone remodelling takes place throughout life at different turnover speed according to age, physiological and pathological conditions. The evaluation of bone turnover may be of value for a prognostic and therapeutical assessment. Calcium bone exchange may be considered a suitable marker of bone turnover; for this reason 47Ca or 45Ca kinetics may be used; these methods have been employed in the past. Labelled diphosphonates, and in particular 99Technetium-methylene-diphosphonate (99TcmDP) are simpler and safer, because these substances are strongly and almost completely stored in bone and not absorbed by the soft tissue; for this reason they are used at the present time. The evaluation of blood levels and 24 hrs urinary elimination of 99TcmDP is used to measure whole bone diphosphonate retention (WBR). This parameter is positively correlated with other markers of bone turnover such as alkaline phosphatase (AP), osteocalcin (OC), urinary hydroxyproline (HOP). A bicompartmental analysis schedule of 99TcmDP distribution has been proposed some years ago and therefore applied by our group, based on the mathematical evaluation of serum concentration at different times and urinary elimination of the label given intravenously. This method provides the possibility to calculate not only WBR but also total body retention (TBR) and a constant (Kbh) which reflects the influx speed of the tracer in the bone. Kbh probably represents a more sensitive index of bone turnover than WBR. It presents a better correlation with AP and OC values and also shows some (statistically less significant correlations with some indices of bone remodelling obtained by histomorphometry on bone biopsies.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2788063     DOI: 10.1007/bf02207231

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  9 in total

1.  Drug therapy. Clinical Pharmacokinetics (first of two parts).

Authors:  D J Greenblatt; J Kock-Weser
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

2.  Estimation of total body calcium from the bone mineral content of the forearm.

Authors:  C Christiansen; P Rödbro
Journal:  Scand J Clin Lab Invest       Date:  1975-09       Impact factor: 1.713

3.  Iliac crest biopsy: an investigation on certain aspects of precision and accuracy.

Authors:  J Pødenphant; A Gotfredsen; L Nilas; H Nørgård; O Braendstrup; C Christiansen
Journal:  Bone Miner       Date:  1986-09

4.  A bone stain for osteoid seams in fresh, unembedded, mineralized bone.

Authors:  A R Villanueva
Journal:  Stain Technol       Date:  1974-01

5.  Optimization of the ratio of stannous tin: ethane-1-hydroxy-1, 1-diphosphonate for bone scanning with 99mTc-pertechnetate.

Authors:  A J Tofe; M D Francis
Journal:  J Nucl Med       Date:  1974-02       Impact factor: 10.057

6.  Kinetics of 99mtechnetium-tin-methylene-diphosphonate in normal subjects and pathological conditions: a simple index of bone metabolism.

Authors:  A Caniggia; A Vattimo
Journal:  Calcif Tissue Int       Date:  1980       Impact factor: 4.333

7.  Clodronate kinetics and bioavailability.

Authors:  G J Yakatan; W J Poynor; R L Talbert; B F Floyd; C L Slough; R S Ampulski; J J Benedict
Journal:  Clin Pharmacol Ther       Date:  1982-03       Impact factor: 6.875

8.  Bone turnover in spinal osteoporosis.

Authors:  J Pødenphant; J S Johansen; K Thomsen; B J Riis; A Leth; C Christiansen
Journal:  J Bone Miner Res       Date:  1987-12       Impact factor: 6.741

9.  The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease.

Authors:  I Fogelman; R G Bessent; J G Turner; D L Citrin; I T Boyle; W R Greig
Journal:  J Nucl Med       Date:  1978-03       Impact factor: 10.057

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.